Found 183 articles
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST).
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the formation of a Scientific Advisory Board.
Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT.
Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 2023, in Brussels, Belgium.
New Clarivate Biopharma Dealmaking Report Reveals Investment Patterns Set to Impact the Future of Medicine
Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, released its new report, Biopharma Dealmaking in 2023.
Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets.
Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.
The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.
Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL.
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
Captor Therapeutics S.A. discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05.
Exscientia plc. Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.
Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets.
Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.
Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor.
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.
Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent program and corporate developments.
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.
Rallybio Corporation provided an update on recent accomplishments and announced expected 2023 clinical milestones.